Long-awaited results from Phase 1/2 studies lifted Sarepta’s stock and, according to the company, suggest potential for two ...
Sarepta Therapeutics (NASDAQ:SRPT) stock is up approximately 20% in early trading on Wednesday after the company released its ...
AI-powered disease detection and care coordination company Viz.ai has announced a partnership with RNAi therapeutics firm ...
Alnylam Pharmaceuticals is a pioneer in designing therapeutics based on RNA interference, or RNAi, a mechanism that occurs naturally in cells and silences overexpressed genes, which often cause ...
Codexis, Inc. (NASDAQ:CDXS) is one of the 10 Best High-Risk Penny Stocks to Buy Right Now. On March 12, Matt Hewitt of ...
Ellipsis Health partners with PromptWell to boost enrollment in patient care programs, while CaryHealth teams up with ...
Efforts Aimed at Facilitating Earlier Diagnosis, Coordinated Care, and Long-Term Patient Impact in ATTR-CM – − Alnylam to ...
Sarepta Therapeutics is navigating a transition from a profitable rare-disease company to a capital-intensive, multi-platform ...
Significant regulatory milestone marks advancement into clinical-stage development of next-generation RNAi therapy featuring an innovative, ...
Why Vertex, Bayer, Alnylam, and Sanofi are among the most innovative companies developing new treatments and medicines.
In this article, we will take a look at the 12 Best Rebound Stocks to Buy Right Now. On March 20, oil prices rose again, ...
As part of the settlement, Moderna will pay Arbutus and Genevant $950 million upfront in July 2026 ("Noncontingent Settlement ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results